NICE guideline [NG17]Published: 26 August 2015 Last updated: 31 March 2022 (NICE)
Diabetes News
Tag: NICE
Type 2 diabetes in adults: management
NICE guideline [NG28]Published: 02 December 2015 Last updated: 31 March 2022 (NICE)
Diabetes (type 1 and type 2) in children and young people: diagnosis and management
NICE guideline [NG18]Published: 01 August 2015 Last updated: 31 March 2022 (NICE)
Type 2 diabetes in adults: management
NICE guideline [NG28]Published: 02 December 2015 Last updated: 15 February 2022
Type 2 diabetes in adults: management
In November 2021, we reviewed the evidence on SGLT2 inhibitors for adults with type 2 diabetes and chronic kidney disease, and made new recommendations (NICE)
Type 2 diabetes in adults: management – glucose monitoring
Consultation documents (NICE)
Determinants of treatment modification before and after implementation of the updated 2015 NICE guideline on type 2 diabetes: a retrospective cohort study
Our results indicate that a first step towards tailored prescribing has been made. However, not all determinants that are important to consider when prescribing second-line glucose lowering agents were of influence on general practitioners’ prescribing (Diabetes Research and Clinical Practice)
Type 1 diabetes in adults: diagnosis and management (update)
You can now review and comment on this draft guideline. The consultation closes on 19 May 2021 at 5pm (NICE)
Dapagliflozin with insulin for treating type 1 diabetes
Technology appraisal guidance [TA597] Published date: 28 August 2019 Last updated: 12 February 2020 (NICE)
New – Hypertension in adults: diagnosis and management added to T2D guidelines
This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular problems such as heart attacks and strokes by helping healthcare professionals to diagnose hypertension accurately and treat it effectively (NICE)
Dapagliflozin with insulin for treating type 1 diabetes
Evidence-based recommendations on dapagliflozin (Forxiga) with insulin for treating type 1 diabetes not controlled by insulin therapy alone in adults with a body mass index (BMI) of at least 27 kg/m2 (NICE)
Dapagliflozin with insulin for treating type 1 diabetes
Recommendations (NICE)
Surveillance proposal consultation document
2019 surveillance of 4 diabetes guidelines (NICE)
Type 2 diabetes mellitus: medicines optimisation priorities
This document summarises the evidence base on type 2 diabetes mellitus: medicines optimisation priorities. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance
Medical devices: information for users and patients
Including blood glucose meters (NICE)
Managing hypertension in people of African origin with diabetes: Evaluation of adherence to NICE Guidelines
This study provides insight into adherence to NICE guidance for managing hypertension in African origin patients with diabetes. Further work should be done to explore the effects of hypertension in this ethnic group and if there is a need for a more refined management guideline (Primary Care Diabetes)
NICE impact diabetes
This report considers how NICE’s evidence-based guidance can contribute to improvements in the prevention and management of diabetes
Type 2 diabetes: prevention in people at high risk
This guideline covers how to identify adults at high risk of type 2 diabetes. It aims to remind practitioners that age is no barrier to being at high risk of, or developing, the condition (NICE)
Obese, overweight with risk factors: liraglutide (Saxenda)
This evidence summary discusses 4 randomised controlled trials (RCTs) in adults who were obese or overweight (BMI 27 kg/m2 or above) with a variety of weight-related comorbidities including dyslipidaemia, hypertension, type 2 diabetes and obstructive sleep apnoea (NICE)
Type 2 diabetes prevention. Standing committee C update
Addendum consultation (NICE)
Glycosmedia is also available as an App: